“Pharmacological risk stratification of Lp(a): diabetes status may refine residual cardiovascular risk beyond ASCVD history” - authors’ reply2026-07-300 PRE AI SSam-Lennart Oftadeh DDirk Müller‐Wieland MMarlo Verket * DOI:10.1093/eurjpc/zwag403OriginalOriginal request for helpShareSaveAbstract En